RxDoctor Payments Data

Gloria Heresi

Pediatric Infectious Diseases · Houston, TXNPI 1689618050

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $21,129 of the $21,927 with a category attached, or 96.4%. Gilead accounts for 97.5% of it on its own, with 7 other manufacturers making up the rest.

$21,927in general payments, 2019–2025

Across 112 payments — averaging $195.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$21K
  • Merck$214
  • Astellas Pharma US Inc$121
  • Melinta Therapeutics, LLC$93
  • Tetraphase Pharmaceuticals, Inc.$57
  • Pfizer$28
  • plus $36 from 2 others
$388,249in research payments, 2019–2025

Across 91 payments — averaging $4266.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$149K
  • Viiv Healthcare Company$93K
  • Paratek Pharmaceuticals, Inc.$62K
  • Hoffmann-la Roche Limited$42K
  • AstraZeneca$23K
  • Gilead$19K
  • plus $340 from 1 others

What the payments were for

  • Consulting fees$21,12996%
  • Travel & lodging$70%
  • Food & beverage$7623%
  • Education$290%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$21,927 in reported general payments places this provider in the 85th percentile of 66 pediatric infectious diseases providers in Texas.

See all pediatric infectious diseases providers in Texas

Other pediatric infectious diseases in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →